PATENT CLAIM ANALYSIS

Application Number: 15761995
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-09
Patent Classification: ["514", "210180"]

Abstract:
Provided herein are methods for treating, preventing, or ameliorating one or more symptoms of a condition, disorder, or disease mediated by a lipid kinase or a protein kinase with benzimidazoles, for example, of Formula I or II, and pharmaceutical compositions thereof. Also provided herein are benzimidazoles, and pharmaceutical compositions thereof; and methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.

Claim (Index 177):
A compound selected from:\n (R)\u2014N-(1-(1-acryloylazepan-3-yl)-9-chloro-6,7-dihydro-1H-[1,4]dioxino-[2\u2032,3\u2032:4,5]benzo[1,2-d]imidazol-2-yl)-2-(trifluoromethyl)isonicotinamide A13-A; (R)\u2014N-(1-(1-acryloylazepan-3-yl)-9-chloro-6,7-dihydro-1H-[1,4]dioxino-[2\u2032,3\u2032:4,5]benzo[1,2-d]imidazol-2-yl)-2-(difluoromethyl)isonicotinamide A14-A; (R)\u2014N-(1-(1-acryloylazepan-3-yl)-7,8-dihydro-1H-[1,4]dioxino[2\u2032,3\u2032:3,4]benzo[1,2-d]imidazol-2-yl)benzamido C11-A; (R)\u2014N-(8-(1-acryloylazepan-3-yl)-2-(hydroxymethyl)-8H-imidazo[4\u2032,5\u2032: 5,6]benzo[1,2-d]oxazol-7-yl)-2-methylisonicotinamide C12-A; (R)\u2014N-(1-(1-acryloylazepan-3-yl)-8-oxo-1,7,8,9-tetrahydroimidazo[4\u2032,5\u2032:3,4]-benzo[1,2-b][1,4]oxazin-2-yl)-2-(trifluoromethyl)isonicotinamide C13-A; (R)\u2014N-(1-(1-acryloylazepan-3-yl)-8-oxo-1,7,8,9-tetrahydroimidazo[4\u2032,5\u2032:3,4]-benzo[1,2-b][1,4]oxazin-2-yl)-2-methylisonicotinamide C14-A; (R)\u2014N-(5-acetamido-1-(1-acryloylazepan-3-yl)-7,8-dihydro-1H-[1,4]dioxino[2\u2032,3\u2032:3,4]-benzo[1,2-d]imidazol-2-yl)-2-(trifluoromethyl)isonicotinamide C15-A; (R)\u2014N-(5-acetamido-1-(1-acryloylazepan-3-yl)-7,8-dihydro-1H-[1,4]dioxino[2\u2032,3\u2032:3,4]-benzo[1,2-d]imidazol-2-yl)-2-(difluoromethyl)isonicotinamide C16-A; (R)\u2014N-(5-acetamido-1-(1-acryloylazepan-3-yl)-7,8-dihydro-1H-[1,4]dioxino[2\u2032,3\u2032:3,4]-benzo[1,2-d]imidazol-2-yl)-2-methylisonicotinamide C17-A; (R)\u2014N-(1-(1-acryloylazepan-3-yl)-9-methyl-8-oxo-1,7,8,9-tetrahydroimidazo-[4\u2032,5\u2032:3,4]benzo[1,2-b][1,4]oxazin-2-yl)-2-(trifluoromethyl)isonicotinamide C18-A; and (R)\u2014N-(1-(1-acryloylazepan-3-yl)-9-methyl-8-oxo-1,7,8,9-tetrahydroimidazo-[4\u2032,5\u2032:3,4]benzo[1,2-b][1,4]oxazin-2-yl)-2-(difluoromethyl)isonicotinamide C19-A; and isotopic variants thereof; and pharmaceutically acceptable salts, solvates, and prodrugs thereof.

Metadata:
- Claim Count in Document: 86.0
- Percentile: 96.0
- Lexical Diversity: 2.025
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15127000', '16005490', '14489231', '13431716', '13830712']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8102284562289073
- 35 USC 102 Novelty (BERT): 0.5726946445948139
- Combined Prediction Score: 0.7864750750654979
- Mean Citation Score: 435.272624
- Max Citation Score: 474.12836
- Similarity Product: 358.7090802896976

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test